21例肝外小叶性乳腺癌转移至胃肠道的病例分析

Noah Switzer , Andrew Lim , Lillian Du , Rani Al-Sairafi , Katia Tonkin , Dan Schiller
{"title":"21例肝外小叶性乳腺癌转移至胃肠道的病例分析","authors":"Noah Switzer ,&nbsp;Andrew Lim ,&nbsp;Lillian Du ,&nbsp;Rani Al-Sairafi ,&nbsp;Katia Tonkin ,&nbsp;Dan Schiller","doi":"10.1016/j.ctrc.2014.11.006","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Invasive lobular carcinoma (ILC) comprises 5–16% of all breast cancers, with its incidence gradually increasing. ILC has a disproportionately higher incidence of spread to the gastrointestinal (GI) system.</p></div><div><h3>Methods</h3><p>This study is a retrospective chart review of all cases of ILC with gastrointestinal metastases seen at a university affiliated tertiary cancer institute between 2005 and 2010, examining demographic, epidemiological, medical, and treatment factors that may have an association with the risk of GI metastases.</p></div><div><h3>Results</h3><p>343 consecutive cases of lobular breast cancer were reviewed, and 21(6%) were found to have GI metastases. The mean age at initial diagnosis of primary tumor was 63 years. Stages at presentation of the breast primary were: Stages 1/2%=73% and stages 3/4=27%. Receptor status of the primary breast cancer was as follows: HER2+=5%, PR+=76%, ER+=90%. The mean age at time of diagnosis of metastatic disease was 67 years. The main presenting symptoms of GI metastatic disease were: incidental finding/asymptomatic (20%), nausea (20%), and abdominal pain (15%). The major sites of extrahepatic gastrointestinal spread were the stomach (52%), peritoneum (38%), and omentum (19%). Average five-year survival from initial diagnosis of ILC was 46%. Five-year survival from diagnosis of gastrointestinal metastasis was 29%.</p></div><div><h3>Conclusions</h3><p>Approximately 1 in 20 patients diagnosed with ILC will have spread to the GI tract, presenting 4 years after their initial primary diagnosis. Future research is needed in developing treatment regimens for these patients, as the 5-year survival is only approximately 1 in 4.</p></div>","PeriodicalId":90461,"journal":{"name":"Cancer treatment communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ctrc.2014.11.006","citationCount":"12","resultStr":"{\"title\":\"Case series of 21 patients with extrahepatic metastatic lobular breast carcinoma to the gastrointestinal tract\",\"authors\":\"Noah Switzer ,&nbsp;Andrew Lim ,&nbsp;Lillian Du ,&nbsp;Rani Al-Sairafi ,&nbsp;Katia Tonkin ,&nbsp;Dan Schiller\",\"doi\":\"10.1016/j.ctrc.2014.11.006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Invasive lobular carcinoma (ILC) comprises 5–16% of all breast cancers, with its incidence gradually increasing. ILC has a disproportionately higher incidence of spread to the gastrointestinal (GI) system.</p></div><div><h3>Methods</h3><p>This study is a retrospective chart review of all cases of ILC with gastrointestinal metastases seen at a university affiliated tertiary cancer institute between 2005 and 2010, examining demographic, epidemiological, medical, and treatment factors that may have an association with the risk of GI metastases.</p></div><div><h3>Results</h3><p>343 consecutive cases of lobular breast cancer were reviewed, and 21(6%) were found to have GI metastases. The mean age at initial diagnosis of primary tumor was 63 years. Stages at presentation of the breast primary were: Stages 1/2%=73% and stages 3/4=27%. Receptor status of the primary breast cancer was as follows: HER2+=5%, PR+=76%, ER+=90%. The mean age at time of diagnosis of metastatic disease was 67 years. The main presenting symptoms of GI metastatic disease were: incidental finding/asymptomatic (20%), nausea (20%), and abdominal pain (15%). The major sites of extrahepatic gastrointestinal spread were the stomach (52%), peritoneum (38%), and omentum (19%). Average five-year survival from initial diagnosis of ILC was 46%. Five-year survival from diagnosis of gastrointestinal metastasis was 29%.</p></div><div><h3>Conclusions</h3><p>Approximately 1 in 20 patients diagnosed with ILC will have spread to the GI tract, presenting 4 years after their initial primary diagnosis. Future research is needed in developing treatment regimens for these patients, as the 5-year survival is only approximately 1 in 4.</p></div>\",\"PeriodicalId\":90461,\"journal\":{\"name\":\"Cancer treatment communications\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.ctrc.2014.11.006\",\"citationCount\":\"12\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer treatment communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213089614000140\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213089614000140","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 12

摘要

浸润性小叶癌(ILC)占所有乳腺癌的5-16%,其发病率逐渐增加。ILC有一个不成比例的高发生率扩散到胃肠道(GI)系统。方法:本研究回顾性分析了2005年至2010年间某大学附属三级癌症研究所的所有ILC合并胃肠道转移病例,检查了可能与胃肠道转移风险相关的人口统计学、流行病学、医学和治疗因素。结果343例小叶性乳腺癌患者中有21例(6%)发生了胃肠道转移。原发肿瘤初诊的平均年龄为63岁。乳腺原发的分期为:1/2%=73%,3/4=27%。原发性乳腺癌的受体状态如下:HER2+=5%, PR+=76%, ER+=90%。诊断为转移性疾病时的平均年龄为67岁。胃肠道转移性疾病的主要表现为:偶然发现/无症状(20%)、恶心(20%)和腹痛(15%)。肝外胃肠道扩散的主要部位为胃(52%)、腹膜(38%)和网膜(19%)。ILC的平均5年生存率为46%。诊断为胃肠道转移的5年生存率为29%。结论:大约1 / 20的ILC患者会在初次诊断后4年内扩散到胃肠道。由于这些患者的5年生存率仅约为1 / 4,因此需要进一步的研究来制定治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Case series of 21 patients with extrahepatic metastatic lobular breast carcinoma to the gastrointestinal tract

Background

Invasive lobular carcinoma (ILC) comprises 5–16% of all breast cancers, with its incidence gradually increasing. ILC has a disproportionately higher incidence of spread to the gastrointestinal (GI) system.

Methods

This study is a retrospective chart review of all cases of ILC with gastrointestinal metastases seen at a university affiliated tertiary cancer institute between 2005 and 2010, examining demographic, epidemiological, medical, and treatment factors that may have an association with the risk of GI metastases.

Results

343 consecutive cases of lobular breast cancer were reviewed, and 21(6%) were found to have GI metastases. The mean age at initial diagnosis of primary tumor was 63 years. Stages at presentation of the breast primary were: Stages 1/2%=73% and stages 3/4=27%. Receptor status of the primary breast cancer was as follows: HER2+=5%, PR+=76%, ER+=90%. The mean age at time of diagnosis of metastatic disease was 67 years. The main presenting symptoms of GI metastatic disease were: incidental finding/asymptomatic (20%), nausea (20%), and abdominal pain (15%). The major sites of extrahepatic gastrointestinal spread were the stomach (52%), peritoneum (38%), and omentum (19%). Average five-year survival from initial diagnosis of ILC was 46%. Five-year survival from diagnosis of gastrointestinal metastasis was 29%.

Conclusions

Approximately 1 in 20 patients diagnosed with ILC will have spread to the GI tract, presenting 4 years after their initial primary diagnosis. Future research is needed in developing treatment regimens for these patients, as the 5-year survival is only approximately 1 in 4.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice Activity of trastuzumab-emtansine (TDM1) in HER2-positive breast cancer brain metastases: A case series Pigmentation of the tongue with lapatinib treatment in a patient with advanced breast cancer: A case report Assessment of chemotherapy strategy using bevacizumab for non-squamous non-small cell lung cancer in a real-world setting: A multi-institutional observational study Multiple nodular lung metastases with no obvious primary showing low positive 18-fluoro deoxyglucose (FDG) uptake on positron emission tomography (PET) scan: A unique case of metastatic ameloblastoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1